PCVX vs. RVMD, EXEL, IBRX, RGEN, HALO, QGEN, CRSP, KRYS, IMVT, and IOVA
Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Revolution Medicines (RVMD), Exelixis (EXEL), ImmunityBio (IBRX), Repligen (RGEN), Halozyme Therapeutics (HALO), Qiagen (QGEN), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Vaxcyte (NASDAQ:PCVX) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Vaxcyte has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.
Vaxcyte has higher earnings, but lower revenue than Revolution Medicines. Vaxcyte is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 8.5% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vaxcyte's return on equity of -32.15% beat Revolution Medicines' return on equity.
Vaxcyte presently has a consensus target price of $78.50, indicating a potential upside of 20.42%. Revolution Medicines has a consensus target price of $41.60, indicating a potential upside of 11.68%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Revolution Medicines.
In the previous week, Revolution Medicines had 4 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Revolution Medicines and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.93 beat Revolution Medicines' score of 0.81 indicating that Vaxcyte is being referred to more favorably in the media.
Revolution Medicines received 31 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 68.82% of users gave Revolution Medicines an outperform vote while only 68.75% of users gave Vaxcyte an outperform vote.
Summary
Revolution Medicines beats Vaxcyte on 11 of the 17 factors compared between the two stocks.
Get Vaxcyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
